Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
about
Combination anastrozole and fulvestrant in metastatic breast cancerTreatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancerPharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancerDelaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerDevelopment of Companion DiagnosticsOptimal management of hormone receptor positive metastatic breast cancer in 2016Treating Elderly Patients With Hormone Receptor-Positive Advanced Breast CancerNewer therapies for the treatment of metastatic breast cancer: a clinical updateManagement of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment optionsThe sequential use of endocrine treatment for advanced breast cancer: where are we?AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015.TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.Are Estrogen Receptor Genomic Aberrations Predictive of Hormone Therapy Response in Breast Cancer?Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrantAntiestrogens: structure-activity relationships and use in breast cancer treatmentEndocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancersTargeting the estrogen pathway for the treatment and prevention of lung cancerEverolimus in postmenopausal hormone-receptor-positive advanced breast cancerESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer - Chapter B: Prevention, Early Detection, Lifestyle, Premalignant Lesions, DCIS, Recurrent and Metastatic Breast Cancer.Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.Emerging therapies for breast cancerFulvestrant in advanced breast cancer: evidence to date and place in therapy.Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trialEmerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancerAGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014.From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models.Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patientsSelective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.Sequential activation of classic PKC and estrogen receptor α is involved in estradiol 17ß-D-glucuronide-induced cholestasis.Simvastatin suppresses breast cancer cell proliferation induced by senescent cellsFulvestrant for the treatment of endometrial cancer.The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.Induced protein degradation: an emerging drug discovery paradigm.Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy.Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer
P2860
Q24595386-1C0B312F-8751-41C4-B588-5C0DBDB5EC39Q26741153-46F19115-76A4-4230-A87B-805493289513Q26746212-E331C871-0272-4B29-8AE6-BDD9A3AA1A2FQ26770482-D240E103-DF82-4B81-8934-86192EEAE331Q26774670-8E76C0B5-66D6-48F0-A74E-665F546379A6Q26777683-8E5B3F73-5DDD-46FD-B2B1-EFE88FC16CC2Q26785496-1835B0C8-2F99-43A1-80A4-F2365E804244Q26865260-89CFABC1-26E5-4E9F-BC0C-DABBBECA4BEEQ26995549-F2B36A7C-0E2F-402A-AAFA-AC52EA410160Q26997396-23849755-321C-4054-A477-8C5A645B1E57Q27343148-B0CBC850-12A1-4FAB-9B4B-1EEC4A6703F5Q27852459-783EA62F-90E1-4589-A0CE-5B22316F80F3Q28074060-63612F32-A68C-462B-9E3F-D7070F970FAAQ28076777-5A9B1A45-580B-464E-8AEA-302E7816BEF3Q28077245-6064AE0C-8D3C-4560-B093-7FC9FF0E6979Q28081872-0765BAEA-4CFF-4496-BBC1-DCE3B93B100CQ28397456-D2853DAB-EBF0-4CFC-A201-1F576FB942E5Q29620676-84547FF6-0064-40C7-BAFA-2D3E1B117E60Q30317067-232AF124-1F2B-4054-ADC9-B443945468B0Q30318240-4A4077E8-353F-4454-AB61-C011B50AB1DAQ30318823-AAFE1175-C765-45F5-B35D-DD23BB4F1BCBQ30413295-51C0C32B-9A62-4572-8786-991A0A7E00FAQ33617949-78BD6AC2-930E-4A5C-9360-5F4C79C9581CQ33887675-2FE9EF0A-89F8-4F5C-ABEF-0A2EBD8C54F1Q33915071-7C4BCC65-B945-4ADE-ADE1-044B0413A196Q33941574-A208F6A1-48CD-4729-83FA-E095DF4317CBQ33993400-10563DCC-9AC1-44DE-818B-B9C9745C1827Q34042768-A9385B30-B1AA-4270-86C6-7ECD5AEE6C17Q34315413-D3A20921-7108-46F6-9F58-6FEEE94AC61BQ34484450-E7AADDF1-6A56-45D8-8295-220A34A1821EQ34485539-96062463-D806-487D-8FEA-8BB4DDCD3F59Q34490225-73A208E0-4404-4148-A35A-A10E7D58FB3CQ34500649-73E29762-0F43-4CA6-A757-5D799CAADFFBQ34504829-0B3B9DE3-4F1E-45D0-A27A-F207A6AE5C0AQ34514391-EAB2E657-0EEB-4E00-8A02-282B4AC48785Q34534031-A782D2A8-7722-4F54-8099-1F859443101BQ34545841-FE8B9A6B-BED9-461E-8A33-ED32495BB224Q34626963-3A3A5D67-7F38-4427-9775-7CB49352B907Q34658267-93818617-CC59-49F0-8BBB-EB6C4880BE3DQ34725685-B801D7A4-A3B7-4342-B8F8-BB48F4625DEB
P2860
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Results of the CONFIRM phase I ...... sitive advanced breast cancer.
@en
Results of the CONFIRM phase I ...... sitive advanced breast cancer.
@nl
type
label
Results of the CONFIRM phase I ...... sitive advanced breast cancer.
@en
Results of the CONFIRM phase I ...... sitive advanced breast cancer.
@nl
prefLabel
Results of the CONFIRM phase I ...... sitive advanced breast cancer.
@en
Results of the CONFIRM phase I ...... sitive advanced breast cancer.
@nl
P2093
P50
P356
P1476
Results of the CONFIRM phase I ...... ositive advanced breast cancer
@en
P2093
Didier Verhoeven
Francisco Sapunar
Guy Jerusalem
Iya Smirnova
José L Pedrini
Kelly Pendergrass
Mikhail R Lichinitser
Roberto Torres
Sally Garnett
P304
P356
10.1200/JCO.2010.28.8415
P407
P577
2010-09-20T00:00:00Z